IgA Nephropathy (IgAN), also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody which is a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses.
IgA nephropathy affects the kidneys by attacking the glomeruli. The glomeruli are sets of looping blood vessels in nephrons which is the tiny working units of the kidneys that filter wastes and remove extra fluid from the blood. The buildup of IgA deposits inflames and damages the glomeruli, causing the kidneys to leak blood and protein into the urine. The damage may lead to scarring of the nephrons that progresses slowly over many years. Eventually, IgA nephropathy can lead to End‐stage Renal Disease (ESRD). Which means the kidneys no longer work well enough to keep a person healthy.
The causes of IgA Nephropathy are not well understood. IgA Nephropathy is a response of the immune system to foreign substances. The immune response is what affects kidneys. People with IgA nephropathy have an increased blood level of IgA that contains less of a special sugar, galactose, than normal. This galactose‐deficient IgA is considered “foreign” by other antibodies circulating in the blood. As a result, these other antibodies attach to the galactose‐deficient IgA and form a clump. This clump is also called an immune complex. Some of the clumps become stuck in the glomerulus of the nephron and cause inflammation and damage.
The IgA Nephropathy market report covers emerging drugs, current treatment practices, IgA Nephropathy market share of the individual therapies, current and forecasted IgA Nephropathy Market Size from 2017 to 2030 segmented by seven major markets. The report also provides detailed current IgA Nephropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
IgA Nephropathy Market Key Facts
As per the study conducted by Lafayette et al. IgA Immunoglobulin A (IgA) nephropathy is the most common form of primary glomerulonephritis, with a global incidence of at least 2.5 per 100,000 per year in adults.
As per the American Kidney Fund, about one in every four adults with IgA nephropathy eventually gets kidney failure/End‐Stage Renal Disease (ESRD). Approximately, one in every 10–20 children gets kidney failure/End‐stage Renal Disease (ESRD) because of IgA nephropathy.
In a study titled “Race/ethnicity and disease severity in IgA nephropathy”, conducted by Hall et al., IgA nephropathy is the most common form of glomerulonephritis (GN) worldwide. Approximately 20– 30% of individuals with IgA Neuropathy develop the end‐stage renal disease (ESRD) by 10–20 years following diagnosis.
Visit For Sample Pages:
Key Benefits of IgA Nephropathy Market Report
IgA Nephropathy market report provides an in-depth analysis of IgA Nephropathy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The IgA Nephropathy market report will help in developing business strategies by understanding the IgA Nephropathy Market trends & developments, key players and future market competition that will shape and drive the IgA Nephropathy market in the upcoming years.
The IgA Nephropathy market report covers IgA Nephropathy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the IgA Nephropathy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The IgA Nephropathy market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted IgA Nephropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of IgA Nephropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The IgA Nephropathy epidemiology section covers insights about historical and current IgA Nephropathy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The IgA Nephropathy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched in the market during the study period. The analysis covers IgA Nephropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Several emerging therapies for IgA Nephropathy are in different stages of clinical development. Some of the key players involved in the development of target therapies for the management of IgA Nephropathy are Omeros (OMS721), Calliditas (Nefecon), Reata (Bardoxolone), Apellis (APL‐2), Novartis (LNP023), Merck KGaA (Atacicept), Retrophin (Sparsentan) and others.
Table of Contents
1. Key Insights
2. Executive Summary
3. IgA Nephropathy Competitive Intelligence Analysis
4. IgA Nephropathy Market Overview at a Glance
5. IgA Nephropathy Disease Background and Overview
6. IgA Nephropathy Patient Journey
7. IgA Nephropathy Epidemiology and Patient Population
8. IgA Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy Unmet Needs
10. Key Endpoints of IgA Nephropathy Treatment
11. IgA Nephropathy Marketed Products
12. IgA Nephropathy Emerging Therapies
13. IgA Nephropathy Seven Major Market Analysis
14. Attribute Analysis
15. IgA Nephropathy Market Outlook (7 major markets)
16. IgA Nephropathy Access and Reimbursement Overview
17. KOL Views on the IgA Nephropathy Market.
18. IgA Nephropathy Market Drivers
19. IgA Nephropathy Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States